MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference
MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. CEO Ofer Gonen will engage in a fireside chat on September 10, 2024, at 3:30 p.m. ET.
The discussion, hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research, will be available via live webcast. Investors and interested parties can access the webcast through a provided link or on MediWound's website under the Events & Presentations page in the Investors section.
This presentation offers an opportunity for investors to gain insights into MediWound's latest developments and future prospects in the field of next-generation enzymatic therapeutics for tissue repair.
MediWound (Nasdaq: MDWD), leader nelle terapie enzimatich per la riparazione dei tessuti, ha annunciato la sua partecipazione al 26° Conferenza Annuale Globale sugli Investimenti H.C. Wainwright. Il CEO Ofer Gonen parteciperà a una chiacchierata informale il 10 settembre 2024, alle 15:30 ET.
La discussione, ospitata da Swayampakula Ramakanth, Direttore Generale, Ricerca Azionaria Senior, sarà disponibile tramite webcast dal vivo. Gli investitori e le parti interessate possono accedere al webcast tramite un link fornito o sul sito web di MediWound nella sezione Eventi e Presentazioni nella parte dedicata agli Investitori.
Questa presentazione offre un'opportunità per gli investitori di acquisire informazioni sugli sviluppi più recenti di MediWound e sulle prospettive future nel campo delle terapie enzimatich di nuova generazione per la riparazione dei tessuti.
MediWound (Nasdaq: MDWD), un líder en terapias enzimáticas para la reparación de tejidos, ha anunciado su participación en la 26ª Conferencia Global Anual de Inversiones H.C. Wainwright. El CEO Ofer Gonen participará en una charla informal el 10 de septiembre de 2024, a las 3:30 p.m. ET.
La discusión, presentada por Swayampakula Ramakanth, Director General, Investigación de Equidad Senior, estará disponible a través de una transmisión en vivo. Los inversores y partes interesadas pueden acceder a la transmisión a través de un enlace proporcionado o en el sitio web de MediWound en la página de Eventos y Presentaciones en la sección de Inversores.
Esta presentación ofrece una oportunidad para que los inversores obtengan información sobre los últimos desarrollos de MediWound y las perspectivas futuras en el campo de las terapias enzimáticas de próxima generación para la reparación de tejidos.
MediWound (Nasdaq: MDWD), 조직 재건을 위한 효소 치료의 선두주자가 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참석한다고 발표했습니다. CEO Ofer Gonen은 2024년 9월 10일 오후 3:30 ET에 진행되는 파이어사이드 채팅에 참여할 예정입니다.
해당 토론은 Swayampakula Ramakanth, 매니징 디렉터, 선임 주식 연구가가 진행하며, 라이브 웹캐스트를 통해 제공됩니다. 투자자 및 관심 있는 당사자는 제공된 링크를 통해 웹캐스트에 접속하거나 MediWound 웹사이트의 투자자 섹션 내 이벤트 및 프레젠테이션 페이지를 통해 접근할 수 있습니다.
이번 발표는 투자자들이 조직 재건을 위한 차세대 효소 치료 분야에서 MediWound의 최신 개발 및 향후 전망에 대해 통찰을 얻을 수 있는 기회를 제공합니다.
MediWound (Nasdaq: MDWD), leader en thérapies enzymatiques pour la réparation des tissus, a annoncé sa participation à la 26ème Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. Le PDG Ofer Gonen prendra part à une discussion informelle le 10 septembre 2024 à 15h30 ET.
La discussion, animée par Swayampakula Ramakanth, Directeur Général, Recherche en Actions Senior, sera disponible via un webinaire en direct. Les investisseurs et les parties intéressées peuvent accéder au webinaire via un lien fourni ou sur le site de MediWound dans la section Événements et Présentations sous la rubrique Investisseurs.
Cette présentation offre une occasion pour les investisseurs d'obtenir des informations sur les derniers développements de MediWound et sur les perspectives futures dans le domaine des thérapies enzymatiques de nouvelle génération pour la réparation des tissus.
MediWound (Nasdaq: MDWD), ein führendes Unternehmen in der enzymatischen Therapie zur Gewebereparatur, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz H.C. Wainwright angekündigt. CEO Ofer Gonen wird am 10. September 2024 um 15:30 Uhr ET an einem Kaminabend-Gespräch teilnehmen.
Die Diskussion, die von Swayampakula Ramakanth, Managing Director, Senior Equity Research, moderiert wird, wird über einen Live-Webcast verfügbar sein. Investoren und Interessierte können über einen bereitgestellten Link auf den Webcast zugreifen oder auf der Website von MediWound unter der Seite für Veranstaltungen & Präsentationen im Bereich für Investoren.
Diese Präsentation bietet Investoren die Möglichkeit, Einblicke in die neuesten Entwicklungen von MediWound und die zukünftigen Perspektiven im Bereich der next-generation enzymatischen Therapien zur Gewebereparatur zu gewinnen.
- None.
- None.
YAVNE, Israel, Sept. 03, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research, on Tuesday, September 10, 2024 at 3:30 p.m. ET at the H.C. Wainwright 26th Annual Global Investment Conference.
A live webcast of the event will be accessible both here and on MediWound’s website, under the Events & Presentations page of the Investors section.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of rapid and effective biologics that improve existing standards of care and patient experiences, while reducing costs and unnecessary surgeries.
MediWound’s first drug, NexoBrid®, is an FDA and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, which can significantly reduce surgical interventions. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline, including the company’s lead drug under development, EscharEx®. EscharEx is a Phase III-ready biologic for the debridement of chronic wounds, offering significant potential advantages over the dominant
For more information visit www.mediwound.com and follow the Company on LinkedIn.
| MediWound Contacts: | |
| Hani Luxenburg | Daniel Ferry |
| Chief Financial Officer | Managing Director |
| MediWound Ltd. | LifeSci Advisors, LLC |
| ir@mediwound.com | daniel@lifesciadvisors.com |
| Media Contact: | |
| Ellie Hanson | |
| FINN Partners for MediWound | |
| ellie.hanson@finnpartners.com | |
| +1-929-588-2008 |
FAQ
When is MediWound (MDWD) presenting at the H.C. Wainwright Global Investment Conference?
Who will be representing MediWound (MDWD) at the H.C. Wainwright conference?
How can investors access MediWound's (MDWD) presentation at the H.C. Wainwright conference?
What is the focus of MediWound's (MDWD) business?
